[Cancer Gene Therapy] Researchers discovered a pronounced overexpression of NAT10 in prostate cancer tissues and cell lines, which correlated with enhanced cellular proliferation, migration, invasion, and overall tumor growth.

[Oncogenesis] Scientists elucidated that BCL-xL is the major pro-survival protein in prostate cancer cell lines after docetaxel treatment, which can be reverted using BH3 mimetics or PROTAC strategies against this protein.

[University of Mississippi Medical Center] University of Mississippi Medical Center research to study the mechanisms of prostate cancer bone metastasis and evaluate new therapies has gained nearly $2.6 million in funding from the National Cancer Institute.

[Nature Reviews Urology] Unconventional T cells — including γδ T cells, mucosal-associated invariant T cells, NK T cells, double-positive and double-negative- T lymphocytes — are an underexplored component of immune surveillance in urological cancers. Emerging evidence suggests that each subset exhibits context-dependent behaviour across prostate cancer, bladder cancer, and renal cell carcinoma.

[Trends in Cancer] Researchers explore the key immune-evasive features of prostate cancer, the contribution of the tumor microenvironment, and the immunotherapeutic strategies that have been clinically evaluated to improve outcomes in patients with advanced disease.

[Clinical Cancer Research] Scientists identified SPEN inactivation as a driver of androgen receptor pathway inhibitor resistance. SPEN inactivation results in upregulation of cell cycle proliferation and basal/stem cell activity as well as increased translation of pro-oncogenic genes.

[Journal of Clinical Investigation] To investigate the immunomodulatory effects of poly(ADP-ribose) polymerase inhibitors in an unbiased manner, researchers performed bulk RNA sequencing on homologous recombination repair-proficient MycCaP cells treated with the PARP inhibitor olaparib versus vehicle control.

[Biochimica Et Biophysica Acta-Molecular Basis of Disease] Investigators identified the chromatin remodeler HELLS as a critical oncogenic driver in prostate cancer and elucidated a previously unrecognized post-translational cascade that governs its protein stability.

[The Journal of Clinical Investigation] Scientists showed that EZH2 inhibitors synergize with PI3K, AKT, or mTORC1 inhibitors to kill CRPC in vitro and promote tumor regression in vivo.

[Amsterdam UMC] KWF announced 34 research projects that will receive funding in its latest round — including 8 projects involving Cancer Center Amsterdam (CCA) researchers.

[Advanced Science] Scientists validated the biological function of HOXC11 in colorectal cancer (CRC) proliferation and metastasis and established its clinical relevance in CRC.

[Cell Reports Methods] Investigators established a scalable, microarrayed 3D human intestinal organoid platform enabling high-throughput, single-organoid-resolution phenotyping of cytokine-induced epithelial injury and recovery.